Can biomarkers guide MS treatment? new trial aims to find out
NCT ID NCT03109288
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether changes in spinal fluid biomarkers can predict which drug or drug combination works best for people with progressive multiple sclerosis (MS). Participants will take one or two of five drugs (cilostazol, leucovorin, pirfenidone, dantrolene, or pioglitazone) for up to 18 months. The goal is to slow disability progression by tailoring treatment to each person's unique disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
What this could lead to
If successful, this could lead to personalized combination therapies for progressive MS, slowing disability progression based on individual biomarkers.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 250 participants, so results may not apply to all MS patients. The drugs may cause side effects or fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••